@article{JTD25081,
author = {Fiachra McHugh and Khalid Ahmed and Antoinette Neylon and Faisal Sharif and Darren Mylotte},
title = {Antithrombotic management after transcatheter aortic valve implantation},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 30},
year = {2018},
keywords = {},
abstract = {Transcatheter aortic valve implantation (TAVI) is now the accepted standard of care for patients with symptomatic severe aortic stenosis at elevated risk for conventional surgical valve replacement. Currently, societal guidelines propose the use of dual antiplatelet therapy for the prevention of thromboembolic events after TAVI in patients without an indication for oral anticoagulation. This strategy is empiric and largely based on expert consensus extrapolated from the arena of percutaneous coronary intervention. In this review, we explore the rational for using antiplatelet and/or anticoagulant strategies after TAVI, review current guidelines and the evidence underpinning them, and detail the on-going randomized trials that will shape future recommendations on this important issue.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25081}
}